Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Intensification in Non-metastatic Ewing Sarcoma (EW-1)
NCT02063022Phase 3Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Jan 2009
- Primary completion
- Apr 2022
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, doxorubicin, ifosfamide, cyclophosphamide, etoposide and 2 more in Ewing sarcoma, sponsored by Italian Sarcoma Group. Started Jan 2009; status: completed.
02
Drugs
vincristinedoxorubicinifosfamidecyclophosphamideetoposide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT02063022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063022.